PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People\'s Republic of China.\', \'Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People\'s Republic of China.\', \'Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, People\'s Republic of China.\', \'Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People\'s Republic of China.\', \'Guangzhou Laboratory, Guangzhou Province, China.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1080/22221751.2022.2051753
?:doi
?:hasPublicationType
?:journal
  • Emerging microbes & infections
is ?:pmid of
?:pmid
?:pmid
  • 35259078
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all